Biomega Laboratories


	Read the LabToWallStreet Out of the Lab article on Biomega Laboratories, Inc.


	Listen to the BioTech Today Interview with Biomega Laboratories, Inc. C.E.O. Richard D. Glaser, PhD.

Biomega Laboratories, Inc. was created

(1) to focus resources on achieving a better understanding of the implications of the observed in vitro and in vivo activity found with the endogenous peptide, Contact Inhibitory Factor™ (CIF™),

(2) to spearhead the development of CIF as a multi-functional drug, bring it to market for the treatment of cancer and ophthalmic indications and

(3) to develop new chemical entities based on the conformation of CIF and bring them to market for more effective treatments of disease.

CIF's unique activity was discovered by Dr. George Lipkin in his work with cancer at New York University School of Medicine (NYUSM). CIF has been synthesized, with the synthetic peptide showing similar activity to the biologically sourced peptide.

Pharmaceutical Implications

Cancer
CIF has been shown to "normalize" the growth of all solid tumors examined in vitro. CIF has been also shown to cause the permanent regression of melanoma and lung carcinoma in hamsters and mice, respectively. The mTOR Pathway, in which CIF is active, is implicated in over 50% of all cancers, with that percentage increasing as more research is conducted on the mTOR Pathway and what it regulates. On this basis along with other factors, Biomega believes that CIF will be effective in the treatment of cancer.

Ophthalmics
The anti-angiogenic effects of CIF as well as its anti-cell proliferative effects suggest that CIF may be effective in the treatment of a number of ophthalmic diseases such as Age Related Wet Macular Degeneration, Proliferative Vitreoretinopathy, and Retinal Neovascularization which includes as its largest segment, Proliferative Diabetic Retinopathy.